Moreover, Mdm2 is amplified and overexpressed in cancer cells, and compounds that promote Mdm2 degradation in cells or inhibit Mdm2 activity are also powerful drug candidates for cancers that harbor wild-type p53. This evidence concerns the gene MDM2 and cancer.